Lupin announces UK MHRA Approval of Lutio® for Treatment of COPD

Global pharma major Lupin Limited (Lupin) announced today that its UK subsidiary, Lupin Healthcare (UK) Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a generic version of Spiriva®. Lutio® has the potential to offer significant cost savings when available to UK patients.

"We are pleased to have received the approval of Lutio® from the MHRA for the treatment of chronic obstructive pulmonary disease (COPD), providing an effective and high-quality treatment option to patients in UK," said Thierry Volle, President, EMEA, Lupin.

Tiotropium is used to relieve wheezing, shortness of breath, coughing, and chest tightness in patients with chronic obstructive pulmonary disease (COPD), a group of diseases that affect the lungs and airways) such as chronic bronchitis and emphysema.

This is the second inhalation product by Lupin Healthcare for the UK market after Luforbec® pressurised metered dose inhaler (pMDI).

Shares of Lupin Limited was last trading in BSE at Rs. 665.00 as compared to the previous close of Rs. 677.65. The total number of shares traded during the day was 88662 in over 4779 trades.

The stock hit an intraday high of Rs. 680.35 and intraday low of 662.05. The net turnover during the day was Rs. 59339262.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 LupinHealthcareUk UKMHRA Approval GenericVersion Spiriva Lutio COPDTreatment